Knight Therapeutics (GUD) Stock Overview
Focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
GUD Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Knight Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$9.91 |
| 52 Week High | CA$9.98 |
| 52 Week Low | CA$5.66 |
| Beta | 0.051 |
| 1 Month Change | 15.10% |
| 3 Month Change | 28.87% |
| 1 Year Change | 63.80% |
| 3 Year Change | 100.61% |
| 5 Year Change | 89.85% |
| Change since IPO | 158.75% |
Recent News & Updates
GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing
Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing
Analysts have revised the fair value estimate for Knight Therapeutics from about CA$12.00 to roughly CA$11.65, reflecting updated assumptions on revenue growth, profit margins and a higher future P/E multiple. Recent Street research also includes higher CA$ price targets and renewed positive coverage.GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing
Analysts have raised their fair value estimate for Knight Therapeutics stock from CA$11.00 to CA$12.00, citing recent price target increases and renewed coverage that highlight modest adjustments to growth and margin assumptions, along with a slightly higher future P/E multiple. Analyst Commentary Bullish analysts have recently adjusted their outlook on Knight Therapeutics, pointing to factors that they see as supportive of the higher fair value estimate.Recent updates
GUD: Latin American Drug Launches And Renewed Coverage Will Drive Future Repricing
Analysts have lifted their price target on Knight Therapeutics by CA$1, reflecting updated assumptions for slightly higher revenue growth and profit margins, along with a modestly lower future P/E multiple. Analyst Commentary Recent research coverage on Knight Therapeutics points to a more constructive tone, with bullish analysts emphasizing the refreshed price target and renewed attention on the stock.GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing
Analysts have revised the fair value estimate for Knight Therapeutics from about CA$12.00 to roughly CA$11.65, reflecting updated assumptions on revenue growth, profit margins and a higher future P/E multiple. Recent Street research also includes higher CA$ price targets and renewed positive coverage.GUD: Latin American Approvals And Buybacks Will Support Future Bullish Repricing
Analysts have raised their fair value estimate for Knight Therapeutics stock from CA$11.00 to CA$12.00, citing recent price target increases and renewed coverage that highlight modest adjustments to growth and margin assumptions, along with a slightly higher future P/E multiple. Analyst Commentary Bullish analysts have recently adjusted their outlook on Knight Therapeutics, pointing to factors that they see as supportive of the higher fair value estimate.GUD: Higher 2026 Margins And Buybacks Will Support Bullish Repricing
Analysts have lifted their price target on Knight Therapeutics by CA$0.50, citing updated assumptions around slightly higher revenue growth, profit margins, and a marginally adjusted future P/E. Analyst Commentary Recent research updates point to a modestly more constructive stance on Knight Therapeutics, with bullish analysts reflecting their view through a CA$0.50 lift in the price target.GUD: Updated 2026 Guidance And Margin Outlook Will Support Bullish Repricing
Analysts have lifted their price target on Knight Therapeutics by CA$0.50, citing updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent research points to a more constructive stance on Knight Therapeutics, with bullish analysts adjusting their models to reflect updated views on revenue trajectories, margin sustainability and future P/E assumptions.GUD: Higher Earnings Visibility And 2026 Guidance Will Support Bullish Repricing
Analysts have raised their blended price target for Knight Therapeutics to CA$11.00, supported by updated assumptions on discount rate, revenue growth, profit margin and future P/E, as well as a recent CA$0.50 target move from Street research. Analyst Commentary Recent research commentary points to a more constructive tone around Knight Therapeutics, with the CA$0.50 increase in one target contributing to a higher blended price target of CA$11.00.Knight Therapeutics' (TSE:GUD) Solid Profits Have Weak Fundamentals
Knight Therapeutics Inc.'s ( TSE:GUD ) robust earnings report didn't manage to move the market for its stock. Our...
Paladin Acquisition And New Launches Will Expand Market Presence
Acquisitions and expanded partnerships bolster Knight's Canadian and oncology revenue, enhancing stability and growth prospects.Knight Therapeutics Inc.'s (TSE:GUD) Popularity With Investors Is Clear
When close to half the companies in the Pharmaceuticals industry in Canada have price-to-sales ratios (or "P/S") below...Knight Therapeutics Inc. (TSE:GUD) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders might have noticed that Knight Therapeutics Inc. ( TSE:GUD ) filed its quarterly result this time last...Shareholder Returns
| GUD | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 4.9% | 2.8% | 1.0% |
| 1Y | 63.8% | 53.0% | 29.8% |
Return vs Industry: GUD exceeded the Canadian Pharmaceuticals industry which returned 53% over the past year.
Return vs Market: GUD exceeded the Canadian Market which returned 29.8% over the past year.
Price Volatility
| GUD volatility | |
|---|---|
| GUD Average Weekly Movement | 4.7% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 9.7% |
| 10% most volatile stocks in CA Market | 16.8% |
| 10% least volatile stocks in CA Market | 3.7% |
Stable Share Price: GUD has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: GUD's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 830 | Samira Sakhia | www.knighttx.com |
Knight Therapeutics Inc. focuses on acquiring, in-licensing, out-licensing, marketing, and commercializing prescription pharmaceutical products in Canada and Latin America. The company offers Minjuvi for relapsed or refractory diffuse large B-cell lymphoma; Pemazyre for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Tavalisse for the treatment of chronic immune thrombocytopenia; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; Lenvima for advanced renal cell cancer; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Bapoci for brest cancer; Xetrane for multiple myeloma; Rembre for chronic myeloid leukemia; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms; IPX203 for Parkinson’s disease; Qelbree for attention-deficit hyperactivity disorder; Jornay PM for attention-deficit hyperactivity disorder; and Crexon for Parkinson’s disease. In addition, it offers Salofalk for ulcerative colitis; Ursofalk for biliary cirrhosis; Fibridoner for idiopathic pulmonary fibrosis; Ibsrela for IBS-C; and Exelon for symptomatic treatment of mild to moderately severe dementia in people with Alzheimer's and Parkinson's disease.
Knight Therapeutics Inc. Fundamentals Summary
| GUD fundamental statistics | |
|---|---|
| Market cap | CA$972.96m |
| Earnings (TTM) | CA$5.61m |
| Revenue (TTM) | CA$510.45m |
Is GUD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GUD income statement (TTM) | |
|---|---|
| Revenue | CA$510.45m |
| Cost of Revenue | CA$275.98m |
| Gross Profit | CA$234.47m |
| Other Expenses | CA$228.86m |
| Earnings | CA$5.61m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.057 |
| Gross Margin | 45.93% |
| Net Profit Margin | 1.10% |
| Debt/Equity Ratio | 7.4% |
How did GUD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/05 02:11 |
| End of Day Share Price | 2026/07/03 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Knight Therapeutics Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Kideckel | Beacon Securities Limited |
| David Martin | Bloom Burton & Co. |